DGX250117P150000
- 1.05
- 0.000.00%
Quest Diagnostics Newsroom
Leerink Partners Upgrades Quest Diagnostics(DGX.US) to Buy Rating, Raises Target Price to $174
Quest Diagnostics Raised to Outperform From Market Perform by Leerink Partners
Quest Diagnostics Analyst Ratings
Mizuho Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Announces Target Price $177
Mizuho Adjusts Price Target on Quest Diagnostics to $177 From $174, Keeps Outperform Rating
Morgan Stanley Upgrades Quest Diagnostics(DGX.US) to Buy Rating, Raises Target Price to $172
Morgan Stanley Upgrades Quest Diagnostics to Overweight From Equalweight, Adjusts Price Target to $172 From $145
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Bicycle Therapeutics (BCYC) and Quest Diagnostics (DGX)
Barclays Initiates Quest Diagnostics(DGX.US) With Hold Rating, Announces Target Price $168
BofA Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Raises Target Price to $182
Quest Diagnostics Price Target Announced at $185.00/Share by Jefferies
Quest Diagnostics Analyst Ratings
Jefferies Initiates Quest Diagnostics(DGX.US) With Buy Rating, Announces Target Price $185
Baird Maintains Quest Diagnostics(DGX.US) With Buy Rating, Cuts Target Price to $181
Baird Adjusts Price Target on Quest Diagnostics to $181 From $182, Keeps Outperform Rating
Quest Diagnostics: Balancing Consistent Performance With Growth Constraints – Hold Rating Maintained
Mizuho Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Equillium (EQ), Quest Diagnostics (DGX) and Alnylam Pharma (ALNY)
Quest Diagnostics Analyst Ratings
Piper Sandler Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $165